Syros Pharmaceuticals, which is developing gene expression therapies based on non-coding DNA research, raised $50 million by offering 4 million shares at $12.50, below the range of $14 to $16. Syros Pharmaceuticals plans to list on the Nasdaq under the symbol SYRS. Cowen & Company and Piper Jaffray acted as lead managers on the deal.
